Walden Biosciences
Dr. Blaine McKee has over 25 years of experience building biotechnology companies and possesses extensive strategic, transactional, and market access expertise. Having worked in both large companies and start-ups, Dr. McKee’s experience includes executive roles at Genzyme Corporation, 480 BioMedical, Shire, and ImmunoGen.
Previously, as Executive Vice President and Chief Business Officer at ImmunoGen, Dr. McKee was responsible for leading the company’s broader corporate development function, including all transactional, alliance management, commercial assessment and planning, and valuation matters. At Shire, he served as Head of Corporate Development, leading the corporate strategy, M&A, business development/licensing, due diligence, commercial assessment, integration, and alliance management functions. Prior to joining Shire, Dr. McKee was Executive Vice President and Chief Business Officer at 480 Biomedical, a venture capital-backed medical device company.
During a 15-year tenure at Genzyme, Dr. McKee held a variety of senior strategy, business development, and market access roles, including serving as Senior Vice President of Strategic Development for the Oncology, Transplant, and Multiple Sclerosis divisions, and leading global business development activities for all three business. He started his career in the biopharmaceutical industry as a Research Scientist at Gilead Sciences, Inc.
Dr. McKee currently serves on the Board of VBI Vaccines Inc., where he is Chairman of the Audit Committee. He previously served on the boards of BioStage, Inc., ArmaGen, Inc., and The New York Pharma Forum. Dr. McKee received a B.S. in Chemistry from Colorado State University, a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology (MIT), and an MBA in Finance from the MIT Sloan School of Management.
Walden Biosciences
Walden Biosciences is a biotechnology company relentlessly focused on developing first-in-class, highly-targeted therapies for individuals living with kidney disease. We are developing breakthrough medicines targeted directly to the kidney and will be successful through our comprehensive knowledge and understanding of novel kidney-specific biological pathways and our team’s track record in drug discovery. Our goal is to transform the treatment of kidney disease by reversing its progression, enabling and inspiring patients to resume their normal lives. Our culture is collaborative and entrepreneurial, and our team is dynamic and driven by data and innovation. We want to make the best decisions with the best available information, lead by example, and bring transformative medicines to patients in need. Walden is based in the heart of Cambridge, MA between Harvard, Massachusetts Institute of Technology (MIT), and Massachusetts General Hospital.